Connor Clark & Lunn Investment Management Ltd. Has $5.13 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 32.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,532 shares of the biotechnology company's stock after acquiring an additional 3,573 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in United Therapeutics were worth $5,127,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. World Investment Advisors LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $139,206,000. FMR LLC increased its holdings in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after buying an additional 314,004 shares during the last quarter. AustralianSuper Pty Ltd raised its position in United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after acquiring an additional 161,751 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Stock Up 5.1 %

NASDAQ:UTHR traded up $15.70 during mid-day trading on Monday, reaching $322.94. 400,603 shares of the company were exchanged, compared to its average volume of 443,935. The stock has a market cap of $14.50 billion, a PE ratio of 14.18, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company has a fifty day moving average of $349.12 and a 200 day moving average of $358.27.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. During the same period in the prior year, the firm earned $4.36 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now owns 5,051 shares of the company's stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 116,464 shares of company stock valued at $42,396,244. Company insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.